Vycor Medical Inc (VYCO) stock
VYCOOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.07+0.00 (0.00%)
Close on Oct 19, 2026Market cap $2.24MP/E –Yield –
Vycor Medical r&d expenses
Research and development expenses are spending on new products and technology.
Vycor Medical's R&D Expenses for the twelve months ending Dec 31, 2025 was $9.96K, down 35.0% year over year. For fiscal 2025 it was $9.96K, down 35.0% from the year before. Over ten years it grew -15.5% a year on average. The highest annual figure on record is $126.04K in fiscal 2012.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.96K | -35.0% |
| FY2024 | Dec 31, 2024 | $15.33K | -32.1% |
| FY2023 | Dec 31, 2023 | $22.56K | +48.8% |
| FY2021 | Dec 31, 2021 | $15.16K | – |
| FY2020 | Dec 31, 2020 | $0 | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2017 | Dec 31, 2017 | $3.02K | -36.4% |
| FY2016 | Dec 31, 2016 | $4.74K | -93.4% |
| FY2015 | Dec 31, 2015 | $71.51K | +3.5% |
| FY2014 | Dec 31, 2014 | $69.11K | +29.3% |
| FY2013 | Dec 31, 2013 | $53.45K | -57.6% |
| FY2012 | Dec 31, 2012 | $126.04K | +9.0% |
| FY2011 | Dec 31, 2011 | $115.67K | +660.6% |
| FY2010 | Dec 31, 2010 | $15.21K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $4.20K | +85.6% |
| Q1 FY2025 | Mar 31, 2025 | $5.76K | +156.1% |
| Q4 FY2024 | Dec 31, 2024 | $6.64K | -8.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.43K | -14.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.26K | -58.9% |
| Q4 FY2023 | Dec 31, 2023 | $2.25K | -66.4% |
| Q3 FY2023 | Sep 30, 2023 | $7.25K | +297.3% |
| Q2 FY2023 | Jun 30, 2023 | $7.55K | +92.2% |
| Q1 FY2023 | Mar 31, 2023 | $5.51K | +104.0% |
| Q4 FY2021 | Dec 31, 2021 | $6.71K | +1044.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.83K | -56.1% |
| Q2 FY2021 | Jun 30, 2021 | $3.93K | – |
| Q1 FY2021 | Mar 31, 2021 | $2.70K | – |
| Q4 FY2016 | Dec 31, 2016 | $586 | – |
| Q3 FY2016 | Sep 30, 2016 | $4.15K | – |
See a number that looks wrong?